6 completed, 1 terminated. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Miricorilant: new trials by email Literature Review of Miricorilant trials Research Report on Miricorilant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Pharmacokinetics and Safety of Miricorilant Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis | Phase 1 | Completed | Corcept Therapeutics | 14 | 2026-04-30 | 2026-10-16 |
| Evaluation of Miricorilant on Liver Fat in Patients With MASLD Miricorilant - Nonalcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH) | Phase 1 | Completed | Corcept Therapeutics | 9 | 2025-08-22 | 2026-09-30 |
| Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant Miricorilant, Fluvoxamine - Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Corcept Therapeutics | 26 | 2023-01-24 | 2023-03-22 |
| Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Miricorilant Miricorilant - Non-alcoholic Steatohepatitis (NASH) | Phase 1 | Completed | Corcept Therapeutics | 19 | 2022-03-03 | 2025-03-30 |
| Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo Miricorilant, Placebo oral tablet - Alcohol Use Disorder | Phase 2 | Completed | The Scripps Research Institute | 50 | 2021-04-15 | 2023-02-03 |
| Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) Miricorilant, Placebo - Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Terminated | Corcept Therapeutics | 12 | 2020-11-04 | 2022-08-31 |
| A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications Miricorilant, Placebo - Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | Completed | Corcept Therapeutics | 71 | 2019-12-04 | 2024-09-19 |
Non-alcoholic Fatty Liver Disease (5) · Alcohol-Related Disorders (1) · Alcoholism (1) · Bipolar Disorder (1) · Mental Disorders (1) · Obesity (1) · Schizophrenia (1) · Weight Gain (1)
Corcept Therapeutics (6) · The Scripps Research Institute (1)
United States (7)
Joseph Custodio, PhD (2) · Kavita Juneja, MD (2) · Aprille Espinueva, PharmD (1) · Barbara J. Mason, Ph.D. (1)
U01AA025476 (1)